← Back to home

HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6

Clinical trials for HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6 explained in plain language.

Never miss a new study

Get alerted when new HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6 trials appear

Sign up with your email to follow new studies for HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

Experimental drug shows promise for Tough-to-Treat lymphoma

Disease control Ongoing

This study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can…

Matched conditions: HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 12:01 UTC

HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6

Get alerted when new HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6 trials appear

Experimental drug shows promise for Tough-to-Treat lymphoma